Google Ads and SEO for GLP-1, semaglutide, and physician-supervised weight loss clinics, built to compete against national telehealth platforms while staying compliant with drug-advertising restrictions.
Get My Free AI Marketing AuditMedical weight loss has become one of the fastest-growing patient acquisition categories in outpatient medicine, driven almost entirely by GLP-1 medications like semaglutide and tirzepatide entering mainstream awareness. Practices offering physician-supervised weight loss programs are seeing search demand that didn't exist three years ago, but the category has also attracted intense competition from national telehealth platforms, compounding pharmacies, and med spas adding weight loss as a service line almost overnight.
Google Ads for GLP-1 and weight loss clinics requires careful compliance handling. Google and Meta both restrict certain drug-brand-name advertising and weight-loss claim language. The effective approach centers campaigns on the clinical service and the physician-supervised model, "medically supervised weight loss," "GLP-1 therapy consultation," rather than drug brand names or before-and-after weight claims that risk disapproval. Done correctly, this still captures the high-intent searches driving the category's growth.
SEO and AEO are especially valuable in this category because patients research extensively before committing, "semaglutide vs tirzepatide," "GLP-1 side effects," "how much weight can I lose on semaglutide." Practices publishing genuinely useful, medically accurate content on these questions position themselves to be cited in Google AI Overviews and ChatGPT answers, exactly the moment a patient is deciding whether to trust a local physician over a telehealth subscription.
Compliance-aware campaigns that capture high-intent GLP-1 and weight loss patients without risking policy disapprovals.
Genuinely useful, medically accurate content that ranks and positions your practice for AI search citations.
Local visibility that differentiates your in-person, physician-supervised program from telehealth-only competitors.
Traditional medical weight loss marketing centered on diet programs, meal replacement, and behavioral coaching. GLP-1 medications have completely reshaped patient expectations and search behavior almost overnight. Patients now arrive already knowing the drug names, the general mechanism, and often the approximate cost, they're evaluating providers on access, monitoring quality, and price transparency rather than being educated on the category from scratch.
The most significant competitive threat is national telehealth and compounding platforms that can offer lower prices through scale and less overhead than a local practice. The local practice's genuine advantage is what telehealth structurally cannot offer: in-person physical exams, same-day dose adjustments when side effects appear, and a physician relationship that catches problems telehealth intake forms miss. Marketing that makes this advantage concrete and specific, rather than a vague "personalized care" claim, converts better against telehealth competition.
Pricing transparency has become a genuine competitive lever in this category. Patients comparison-shop aggressively given the significant monthly cost of GLP-1 therapy, and practices that publish clear program pricing rather than requiring a consultation to learn cost consistently see lower bounce rates and higher-intent inquiries, even when their price is not the lowest in the market.